CA3282526A1 - Thiol isomerases inhibitors and use thereof - Google Patents

Thiol isomerases inhibitors and use thereof

Info

Publication number
CA3282526A1
CA3282526A1 CA3282526A CA3282526A CA3282526A1 CA 3282526 A1 CA3282526 A1 CA 3282526A1 CA 3282526 A CA3282526 A CA 3282526A CA 3282526 A CA3282526 A CA 3282526A CA 3282526 A1 CA3282526 A1 CA 3282526A1
Authority
CA
Canada
Prior art keywords
inhibitors
thiol isomerases
isomerases
thiol
isomerases inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3282526A
Other languages
English (en)
Inventor
Daniel Kennedy
Jonathan GIBBINS
Lisa-Marie HOLBROOK
Original Assignee
Western New England University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western New England University filed Critical Western New England University
Publication of CA3282526A1 publication Critical patent/CA3282526A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3282526A 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof Pending CA3282526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762451858P 2017-01-30 2017-01-30
US62/451,858 2017-01-30
CA3052071A CA3052071A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3052071A Division CA3052071A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CA3282526A1 true CA3282526A1 (en) 2025-10-30

Family

ID=62978426

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3282526A Pending CA3282526A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof
CA3052071A Pending CA3052071A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3052071A Pending CA3052071A1 (en) 2017-01-30 2018-01-29 Thiol isomerases inhibitors and use thereof

Country Status (6)

Country Link
US (2) US11872210B2 (https=)
EP (1) EP3585809B1 (https=)
JP (3) JP7272655B2 (https=)
BR (1) BR112019015721A2 (https=)
CA (2) CA3282526A1 (https=)
WO (1) WO2018140858A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164874A1 (en) 2018-02-20 2019-08-29 Western New England University Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用
AU2022276190A1 (en) 2021-05-19 2024-01-18 Quercis Pharma AG Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) * 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions
CN120187701A (zh) * 2022-08-19 2025-06-20 西新英格兰大学 硫醇异构酶抑制剂及其制备方法和使用方法
WO2025094946A1 (ja) * 2023-10-30 2025-05-08 国立大学法人東海国立大学機構 抗体又はその抗原結合性断片、がんの治療用キット、及びがんの治療用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825413B (en) 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4985465A (en) 1989-07-14 1991-01-15 Hendler Sheldon S Method for inhibiting viral and retroviral infections
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
GB9027018D0 (en) 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
ES2333979T3 (es) * 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
KR100649009B1 (ko) 2004-12-30 2006-11-27 동부일렉트로닉스 주식회사 시모스 이미지 센서의 광감지 소자 및 그의 제조방법
EP3087969B1 (en) 2005-05-20 2021-06-30 Jack L. Arbiser Proteasome inhibitors and uses thereof
WO2007070875A1 (en) 2005-12-15 2007-06-21 Aerosol Science Laboratories, Inc. Treatment of active infections and related compositions
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
DE102007001804A1 (de) 2007-01-12 2008-07-17 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von GABAB-Rezeptor selektiven Agonisten zur Behandlung entzündlicher Hauterkrankungen
EP2269076A4 (en) 2008-03-14 2011-04-06 Nat Jewish Health METHOD FOR DETERMINING THE RECOMMENDATION FOR TREATMENT WITH LEUKOTRIA MODIFIERS
WO2009152454A1 (en) 2008-06-12 2009-12-17 The Johns Hopkins University Methods for treating or preventing brain infections
WO2013055674A1 (en) 2011-10-10 2013-04-18 The University Of Toledo Method for treating infections
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US9616056B2 (en) 2013-03-15 2017-04-11 Institute For Cancer Research Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma
WO2014175253A1 (ja) * 2013-04-22 2014-10-30 株式会社栃木臨床病理研究所 抗腫瘍剤
US20160145209A1 (en) * 2013-06-21 2016-05-26 The Broad Institute, Inc. Compounds and compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
GB201321089D0 (en) * 2013-11-29 2014-01-15 Univ East London Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
WO2016118639A1 (en) * 2015-01-20 2016-07-28 The Trustees Of Columbia University In The City Of New York Small molecule oxidizers of pdi and their use
JP6528314B2 (ja) * 2015-03-20 2019-06-12 国立大学法人山口大学 Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤

Also Published As

Publication number Publication date
JP7272655B2 (ja) 2023-05-12
EP3585809B1 (en) 2025-07-02
EP3585809A1 (en) 2020-01-01
EP3585809A4 (en) 2021-02-24
US20210008032A1 (en) 2021-01-14
WO2018140858A1 (en) 2018-08-02
CA3052071A1 (en) 2018-08-02
US20240108600A1 (en) 2024-04-04
JP2023030014A (ja) 2023-03-07
JP2020514411A (ja) 2020-05-21
BR112019015721A2 (pt) 2020-03-24
US11872210B2 (en) 2024-01-16
JP2024161023A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
IL268206A (en) Antibodies directed against bcma and their use
EP3658557A4 (en) TYK2 INHIBITORS AND USES THEREOF
CA3283159A1 (en) Protein degraders and uses thereof
IL270330B (en) Beta-lactamase inhibitors and their uses
SG11202104404XA (en) Erk inhibitors and uses thereof
IL282350A (en) Bernani-RGMC inhibitors and their use
EP3870173A4 (en) WDR5 INHIBITORS AND MODULATORS
CA3282526A1 (en) Thiol isomerases inhibitors and use thereof
EP3567054A4 (en) ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
LT3621694T (lt) Lrrc33 inhibitoriai ir jų panaudojimas
AU2017271189A1 (en) Cytosol-penetrating antibody and use thereof
EP3699193A4 (en) ANTI-VISTA ANTIBODIES AND USE THEREOF
EP3733706A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
EP3796979B8 (en) Mir-181 inhibitors and uses thereof
EP3731840A4 (en) NADPH OXIDASE INHIBITORS AND THEIR USE
EP3758738A4 (en) MODIFIED PLYSS2-LYSINE AND USES THEREOF
EP3749691A4 (en) ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
EP3524254A4 (en) LIN28A ACTIVATOR AND USE OF IT
EP3724657A4 (en) Anti-cannabidiol antibody and uses thereof
EP3729351A4 (en) FAST AND SHEET RESILIENT BLOCK STRINGS
EP3604336A4 (en) ANTI-EMAP II ANTIBODIES AND THEIR USES
EP3672597A4 (en) ARF6 INHIBITORS AND RELATED PROCEDURES
EP3301095A4 (en) Novel phosphodiesterase type-5 inhibitor and application thereof
HK40059660A (en) Rgmc-selective inhibitors and use thereof

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20250808

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: ---D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250808

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: ---W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250808

Free format text: ST27 STATUS EVENT CODE: ---W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250808

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20251016

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251016

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251016

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY DOCUMENT OR RESPONSE DETERMINED COMPLIANT

Effective date: 20251016

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251016

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251016

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251016

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251020

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251020

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20251030

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260312